AstraZeneca and Merck Present P-III (PAOLA-1) & (SOLO-1) Trial Results of Lynparza (olaparib) as 1L Treatment of Advanced Ovarian Cancer at ESMO
Shots:
- The P-III (PAOLA-1) trial evaluates Lynparza + bevacizumab vs bevacizumab + PBO and the (SOLO-1) trial evaluates Lynparza as monothx. vs PBO for advanced ovarian cancer
- The 5 & 7yr. follow-up of (PAOLA-1) & (SOLO-1) trial showed an improvement in OS in HRD+ patients & gBRCAm newly diagnosed advanced ovarian cancer with a 38% & 45% reduction in risk of death; m-OS (not reached vs 52.0mos.) & (not reached vs 75.2mos.), patients were alive (65.5% vs 48.4%) & (67% vs 47%). In (PAOLA-1) trial, improvement in m-PFS (46.8mos. vs 17.6mos.), patients remain progression-free (46.1% vs 19.2%)
- In (SOLO-1) trials, 45% vs 21% were alive & not received a first subsequent treatment. The safety & tolerability profile was consistent with prior trials with no new safety signals
Ref: Merck | Image: AstraZeneca
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
